Healthcare Providers and Services
Company Overview of Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. engages in the patient-specific analyses of cancer genome using digital characterization and monitoring technologies. The company provides METDetect Assay for the detection of MET gene amplifications in the circulation of cancer patients with reports that include identification and schematic representation of tumor-specific MET amplifications, annotation of predicted mutation consequences, data summary statistics, and integrated analysis reporting. Personal Genome Diagnostics, Inc. was founded in 2010 and is based in Baltimore, Maryland.
855 North Wolfe Street
Baltimore, MD 21205
Founded in 2010
Key Executives for Personal Genome Diagnostics, Inc.
Co-Founder and Chief Medical Officer
Co-Founder and Chief Scientific Officer
Compensation as of Fiscal Year 2013.
Personal Genome Diagnostics, Inc. Key Developments
Personal Genome Diagnostics, Inc. Announces Launch of its METDetect(TM) Assay for the Detection of MET Gene Amplifications in the Circulation of Cancer Patients
Apr 2 14
Personal Genome Diagnostics, Inc. announced the launch of its METDetect(TM) Assay for the detection of MET gene amplifications in the circulation of cancer patients. Amplifications and other structural changes of the MET cancer gene have been associated with resistance to therapy and as major oncogenic drivers in a variety of tumors, including colorectal, lung, gastric, brain and head and neck cancer. PGDx's METDetect assay utilizes the company's PARE technology to uniquely identify structural alterations in the MET gene in circulating tumor DNA (ctDNA) directly from the patient's plasma, thereby eliminating the need for invasive and costly tumor biopsies. The METDetect test uses next generation sequencing (NGS) and PGDx's proprietary high sensitivity PARE and other technologies to identify focal amplifications of the MET gene that can be useful for prediction of therapeutic response, overall prognosis and cancer recurrence, and for ongoing monitoring. Analyses are performed in PGDx's CLIA laboratory certified for high complexity clinical testing and take two to three weeks. The comprehensive report includes identification and schematic representation of tumor-specific MET amplifications, annotation of predicted mutation consequences, data summary statistics and integrated analysis reporting. The METDetect assay is CLIA-approved and immediately available for clinical and investigative use.
Personal Genome Diagnostics and MolecularMD Collaborate to Provide Advanced Genomic Testing Services to Cancer Drug Developers
Oct 25 13
Personal Genome Diagnostics, Inc. announced that it will collaborate with MolecularMD to market a suite of comprehensive personalized medicine services to oncology researchers and drug developers, adding PGDx’s expertise in Next-Generation Sequencing (NGS)-based cancer biomarker discovery to MolecularMD’s capabilities in the development, validation and global delivery of cancer companion diagnostics. The collaboration is designed to provide a unique specialized service to the pharmaceutical and biotechnology industry, seamlessly spanning the entire spectrum of genomic and clinical trial services used in new drug R&D and clinical development. Under the terms of the agreement, the two companies will co-market each other’s services to their pharmaceutical and biotechnology customers. PGDx provides advanced genome mapping services and analyses to oncology researchers, clinicians and patients. It employs cancer exome analysis, which enables comprehensive, reliable and unbiased genome-wide identification of cancer-related mutations. The company’s proprietary methods for genome sequencing and analysis are complemented by its deep expertise in cancer genomics. MolecularMD provides molecular diagnostics products and services to pharmaceutical and biotechnology drug developers. Its capabilities range from specialty molecular testing services performed in its CLIA-certified and CAP-accredited laboratory to development of companion diagnostics that support new drug registrations. It also provides NGS services for clinical trials, including standard and custom-designed panels that can profile gene alterations relevant to therapeutic response or resistance.
Personal Genome Diagnostics, Inc. and Blueprint Medicines Corp. form Collaboration to Identify Novel Kinase Targets
May 21 13
Personal Genome Diagnostics, Inc. announced that it will use its proprietary methodologies and expertise in genomic analysis of defined cancer subtypes to identify novel kinase targets in collaboration with Blueprint Medicines Corp. PGDx is an innovator in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, and Blueprint Medicines is an expert in developing highly selective kinase inhibitors for a genetically defined patient population. PGDx leverages the deep expertise of its scientific founders, who are internationally recognized leaders in cancer genomics at Johns Hopkins University, and its proprietary technologies to provide advanced genome-mapping services and analyses to oncology researchers, drug developers and clinicians. The founders of PGDx were the first to analyze the entire set of kinase genes in tumors, the "kinome", and have identified alterations in a variety of protein and lipid kinases, including the discovery of alterations in PIK3CA, one of the most frequently mutated genes in human cancer. PGDx has also been a pioneer in enabling scientists and clinicians to comprehensively analyze entire exomes and genomes to identify novel cancer alterations. As part of the collaboration, PGDx will employ a number of technologies including cancer exome analysis to capture and selectively analyze tumor sequences. These approaches, when combined with other patented PGDx technologies and computational methods, enable comprehensive analysis and unbiased detection of novel cancer-related mutations.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 7, 2014